BHC.TO - Bausch Health Companies Inc.

Toronto - Toronto Delayed Price. Currency in CAD
30.27
+0.19 (+0.63%)
At close: 4:15PM EDT
Stock chart is not supported by your current browser
Previous Close30.08
Open30.26
Bid30.24 x 0
Ask30.25 x 0
Day's Range29.98 - 30.37
52 Week Range23.60 - 36.52
Volume362,072
Avg. Volume715,004
Market Cap10.652B
Beta (3Y Monthly)1.75
PE Ratio (TTM)N/A
EPS (TTM)-4.61
Earnings DateAug 6, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2010-11-10
1y Target Est23.55
  • Bausch Health CEO: Most of our medicines aren't subject to U.S. drug regulations
    CNBC Videos2 months ago

    Bausch Health CEO: Most of our medicines aren't subject to U.S. drug regulations

    Jim Cramer chats with Bausch Health CEO Joe Papa about the company's turnaround and how it's affected by drug pricing.

  • PR Newswire4 days ago

    Court Upholds The Validity And Determined Actavis' Infringement Of Patent Protecting RELISTOR® Tablets

    BRIDGEWATER, N.J. and NEW YORK, July 17, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") and Progenics Pharmaceuticals (PGNX), announced today that the U.S. District Court of New Jersey upheld the validity and determined Actavis' infringement of a patent protecting RELISTOR® (methylnaltrexone bromide) tablets, expiring March 2031. Defendant, Actavis Laboratories FL, Inc., a subsidiary of Teva Pharmaceutical Industries Ltd, had challenged the validity of and had alleged non-infringement of Claims 2 and 5 of U.S. Patent No. 8,524,276, which protects the formulation of RELISTOR® tablets.

  • PR Newswire12 days ago

    Bausch + Lomb Announces U.S. Launch Of Ocuvite® Eye Performance Vitamins

    BRIDGEWATER, N.J., July 9, 2019 /PRNewswire/ -- Bausch + Lomb, a leading global eye health company and wholly owned subsidiary of Bausch Health Companies Inc. (NYSE/TXS: BHC), today announced the U.S. launch of Ocuvite® Eye Performance vitamins, a nutritional supplement designed to meet the changing needs of consumers while further expanding the company's eye vitamin portfolio. "Today's modern, always-on world has evolved faster than our eyes – from the blue light of computer screens and cell phones to the increased UV exposure from the sun – which can have an impact on our eye health," said Joe Gordon, U.S. president, Bausch + Lomb.

  • PR Newswire13 days ago

    Bausch Health Companies Inc. Will Release Second-Quarter 2019 Financial Results On August 6

    LAVAL, Quebec , July 8, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") will release its second-quarter 2019 financial results on Tuesday, Aug. 6, 2019 . Bausch ...

  • Is Bausch Health Becoming a Successful Turnaround Story?
    Market Realist16 days ago

    Is Bausch Health Becoming a Successful Turnaround Story?

    Bausch Health (BHC) has gained 20.13% in the last month and is up by 38.93% in 2019 on a YTD basis.

  • Why Shares of Bausch Health Companies Rocketed Higher in June
    Motley Fool17 days ago

    Why Shares of Bausch Health Companies Rocketed Higher in June

    It was one of the best-performing healthcare stocks last month. Two new product launches and a big debt repayment were the primary contributors.

  • Benzinga19 days ago

    6 Times These Big Investors Probably Said 'Whoops!'

    Pershing Square Capital’s Bill Ackman has had a roller-coaster of success and failures in recent years. Perhaps no failure has been as highly publicized as his stake in Valeant Pharmaceuticals, which is now Bausch Health Companies Inc (NYSE: BHC). Ackman reportedly first took his massive stake in Valeant back in 2015 at an average price of around $196 per share.

  • Here's Why Dova Pharmaceuticals Stock Jumped Higher Today
    Motley Fool24 days ago

    Here's Why Dova Pharmaceuticals Stock Jumped Higher Today

    The drugmaker's Doptelet therapy just received an expanded approval.

  • TheStreet.com26 days ago

    Bausch Health Gains on Debt Reduction, Psoriasis-Lotion Launch

    gained on Tuesday after the health-sciences company said it had reduced its debt outstanding and introduced a new psoriasis-treatment lotion. The Laval, Quebec, company said it had paid down an additional $100 million of debt using cash from operations, eliminating any additional "mandatory amortization" for its fiscal 2020 first quarter. Calling the drug one of its "significant seven" -- a collection of products that could garner a predicted $1 billion in sales through 2024 -- Bausch Health expects Duobrii to be a strong revenue driver.

  • Benzinga26 days ago

    Bausch Sees Clearer With Less Debt

    Bausch Health Companies Inc (NYSE: BHC ) jumped 3% on Tuesday after the company announced it has taken a major stride in paying down its massive debt load. Bausch, which changed its name from Valeant Pharmaceuticals ...

  • PR Newswire26 days ago

    Bausch Health To Reduce Debt By Additional $100 Million Using Cash Generated From Operations

    LAVAL, Quebec, June 25, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") today announced it put in notice to pay down an additional $100 million of its senior secured term loans this week, using cash generated from operations. After this payment, the Company will have eliminated all mandatory amortization for the first quarter of 2020. Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global company whose mission is to improve people's lives with our health care products.

  • PR Newswire26 days ago

    Bausch Health Announces U.S. Launch of DUOBRII™ (halobetasol propionate and tazarotene) Lotion 0.01%/0.045% for Plaque Psoriasis in Adults

    LAVAL, Quebec, June 25, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) and its dermatology business, Ortho Dermatologics, one of the largest prescription dermatology health care businesses, today announced that DUOBRII™ (halobetasol propionate and tazarotene) Lotion, 0.01%/0.045%, will be available commercially to health care professionals starting this week. Approved by the U.S. Food and Drug Administration on April 25, 2019, DUOBRII is the first and only topical lotion that contains a unique combination of halobetasol propionate and tazarotene in one formulation. "The launch of DUOBRII marks the fifth innovative therapy that Ortho Dermatologics has brought forward within the last 30 months," said Bill Humphries, president, Ortho Dermatologics.

  • Barrons.com27 days ago

    Another Women’s Libido Drug, Vyleesi, Won FDA Approval. Stock Investors Aren’t Happy.

    It has been a roller-coaster day on the market for the two companies behind Vyleesi, an injection that received Food and Drug Administration approval last week to treat low sex drive in women. The drug’s approval received significant news coverage, and much of it focused on the controversy that surrounded the other drug approved for low sex drive in women, Addyi, which has struggled on the market and drawn criticism for its potential side effects. The approval of Addyi, marketed by Sprout Pharmaceuticals, drew significant attention in 2015, and led to the $1 billion acquisition of Sprout by (BHC) now (BHC) (BHC).

  • PR Newswirelast month

    Bausch + Lomb ULTRA® Multifocal for Astigmatism Contact Lenses Now Available In the United States

    BRIDGEWATER, N.J., June 19, 2019 /PRNewswire/ -- Bausch + Lomb, a leading global eye health company and wholly owned subsidiary of Bausch Health Companies Inc. (NYSE/TXS: BHC), today announced the U.S. launch of Bausch + Lomb ULTRA® Multifocal for Astigmatism contact lenses, the first and only multifocal toric lens available as a standard offering in the eye care professional's fit set. The new monthly silicone hydrogel lens, which was specifically designed to address the lifestyle and vision needs of patients with both astigmatism and presbyopia, combines the company's unique 3-Zone Progressive™ multifocal design with the stability of its OpticAlign® toric design to provide eye care professionals and their patients an advanced contact lens technology that offers the convenience of same-day fitting during the initial lens exam.

  • Markitlast month

    See what the IHS Markit Score report has to say about Bausch Health Companies Inc.

    Bausch Health Companies Inc NYSE:BHCView full report here! Summary * Perception of the company's creditworthiness is positive * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for BHC with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting BHC. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding BHC totaled $1.20 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swap | PositiveThe current level displays a positive indicator. BHC credit default swap spreads are near the lowest level of the last three years and indicate the market's continued positive perception of the company's credit worthiness.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Biotech Sector Could Enter Bear Market
    Investopedia2 months ago

    Biotech Sector Could Enter Bear Market

    Institutional players are abandoning biotech funds at a rapid pace, raising the odds that the sector will enter a bear market.

  • PR Newswire2 months ago

    Bausch Health Companies Announces Participation in Upcoming Investor Conferences

    LAVAL, Quebec , May 29, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) today announced that the Company will participate in two investor conferences in June. Paul S. Herendeen , executive ...

  • PR Newswire2 months ago

    Bausch Health Announces Early Tender Results and Early Settlement Date for Cash Tender Offers for Senior Notes

    LAVAL, Quebec, May 23, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health," the "Company" or the "Offeror") announced today the results to date of its pending cash tender offers (collectively, the "Tender Offers," and each offer to purchase a series of notes individually, a "Tender Offer") to purchase up to $1,500,000,000 aggregate principal amount (the "Aggregate Maximum Purchase Amount") of its outstanding notes listed in the table below (collectively, the "Notes"), as well as the anticipated early settlement date for the Tender Offers on May 24, 2019 (the "Early Settlement Date"). The terms and conditions of the Tender Offers are described in an Offer to Purchase dated May 9, 2019 (as it may be amended or supplemented from time to time, the "Offer to Purchase") and the related Letter of Transmittal.

  • Better Turnaround Play: Bausch Health Companies or Teva Pharmaceutical Industries
    Motley Fool2 months ago

    Better Turnaround Play: Bausch Health Companies or Teva Pharmaceutical Industries

    Which of these fallen stars has the more compelling comeback story?

  • TheStreet.com2 months ago

    Bausch Health: Long-Term Promise or Stalled at the Top of the Range?

    In his second "Executive Decision" segment of his popular Mad Money program Thursday night, Jim Cramer sat down with Joe Papa, chairman and CEO of Bausch Health Cos. Papa started off by stating that it's the first anniversary of Lumify, BHC's newest treatment for red eyes, and already the product is among the most recommended by doctors and is selling at a $50 million annual run rate. Papa noted that BHC's strength comes from its diversification.

  • BHC’s Salix Segment: Xifaxan Drove Its Revenues in Q1
    Market Realist2 months ago

    BHC’s Salix Segment: Xifaxan Drove Its Revenues in Q1

    Bausch Health Companies: An Attractive Pick after Q1 Results?(Continued from Prior Part)Salix segment performanceIn the first quarter, Bausch Health Companies (BHC) reported revenues of $445 million for its Salix segment—a rise of 5% YoY

  • PR Newswire2 months ago

    Bausch Health Announces Pricing Of Private Offering Of Senior Notes

    LAVAL, Quebec, May 9, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") announced today that it has priced its previously announced offering of $750,000,000 aggregate principal amount of 7.000% senior notes due 2028 (the "2028 Notes") and $750,000,000 aggregate principal amount of 7.250% senior notes due 2029 (the "2029 Notes" and, together with the 2028 Notes, the "Notes"). The 2028 Notes will be sold to investors at a price of 100.00% of the principal amount thereof and the 2029 Notes will be sold to investors at a price of 100.00% of the principal amount thereof. Bausch Health intends to use the net proceeds from the offering of the Notes, along with cash on hand, to repurchase $1,500 million aggregate principal amount across the Company's outstanding 5.50% Senior Notes due 2023 (the "5.50% Notes") and 5.875% Senior Notes due 2023 (the "5.875% Notes" and, together with the 5.50% Notes, the "Existing Notes"), pursuant to its previously announced tender offers, and to pay related fees and expenses.

  • What’s BHC’s Major Revenue Driver in Fiscal 2019?
    Market Realist2 months ago

    What’s BHC’s Major Revenue Driver in Fiscal 2019?

    Bausch Health Companies: An Attractive Pick after Q1 Results?(Continued from Prior Part)Bausch + Lomb/International segmentIn the first quarter, Bausch Health Companies (BHC) reported combined YoY (year-over-year) organic revenue growth of 7% for